Abstract
Furazano[3,4-b]quinoxaline 1-oxides indicate significant chemical reactivity and release NO fragments in their electron impact mass spectra. A series of fused furazan N-oxide derivatives were synthesized and tested in vitro as potential NO releasing agents in the presence of L- cysteine used as a thiol cofactor. The synthesized compounds were determined using cysteine as cofactor and Griess reagent. The yield in nitrite for each compound was expressed as % NO2- (mol/mol). Compound 4c showed the higher NO releasing ability among the tested furazan N-oxide derivatives. A new class of NO-donors, Furazano[3,4-b]quinoxaline 1-Oxides hybrids was developed by joining NOdonor furoxan moiety to substituted quinoxaline 1-Oxides. It seems that lipophilicity and stereochemistry of the X substitution influences the NO donating behavior.
Keywords: Nitric oxide, NO donors, furazano[3, 4-b]quinoxaline 1-Oxides, griess.
Letters in Drug Design & Discovery
Title:In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents
Volume: 13 Issue: 5
Author(s): Kosmas I. Stoitsis, Petros Gkizis, Emmanouella Basgiouraki, John K. Gallos and Dimitra Hadjipavlou-Litina
Affiliation:
Keywords: Nitric oxide, NO donors, furazano[3, 4-b]quinoxaline 1-Oxides, griess.
Abstract: Furazano[3,4-b]quinoxaline 1-oxides indicate significant chemical reactivity and release NO fragments in their electron impact mass spectra. A series of fused furazan N-oxide derivatives were synthesized and tested in vitro as potential NO releasing agents in the presence of L- cysteine used as a thiol cofactor. The synthesized compounds were determined using cysteine as cofactor and Griess reagent. The yield in nitrite for each compound was expressed as % NO2- (mol/mol). Compound 4c showed the higher NO releasing ability among the tested furazan N-oxide derivatives. A new class of NO-donors, Furazano[3,4-b]quinoxaline 1-Oxides hybrids was developed by joining NOdonor furoxan moiety to substituted quinoxaline 1-Oxides. It seems that lipophilicity and stereochemistry of the X substitution influences the NO donating behavior.
Export Options
About this article
Cite this article as:
I. Stoitsis Kosmas, Gkizis Petros, Basgiouraki Emmanouella, K. Gallos John and Hadjipavlou-Litina Dimitra, In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents, Letters in Drug Design & Discovery 2016; 13 (5) . https://dx.doi.org/10.2174/1570180812666150923235828
DOI https://dx.doi.org/10.2174/1570180812666150923235828 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1), a Relevant Target for Diabetic Vasculopathy?
Cardiovascular & Hematological Disorders-Drug Targets Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Technological Innovations in Magnetic Resonance for Early Detection of Cardiovascular Diseases
Current Pharmaceutical Design The Association Between Diabetes and Cognitive Function in Later Life
Current Aging Science Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact
Current Pharmaceutical Design Plasma Potassium Levels in Healthy Prehypertension Subjects and the Role of A High Potassium Drink
Current Hypertension Reviews Nocturnal Blood Pressure Abnormalities in Obstructive Sleep Apnea - Clinical Predictors
Current Respiratory Medicine Reviews Drugs in Pediatric Ischemic Stroke
Current Drug Targets